Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cohen and Millstein to take on lawsuit on contingency,
At 27 modules and 1.7 million total pages,
This is a list of posters who are well versed in NWBO and always a good read and whose opinion I seriously consider. I read their posts with regard even if once in a while I differ on some minor point. There are of course others like them who do not appear on this list.
LG's comment about the backlog is puzzling. Why did NWBO/Advent not hire sufficient workers to handle the number of patients seeking treatment
Yes, of course you are right. I actually knew that, but my fingers were doing the walking. The obvious reason for the choice of the term of art is that to "dismiss a motion to dismiss" gets to be a little confusing, hence the choice of deny, making it to "deny a motion to dismiss." Actually when I wrote this in my post it was "dismiss an MTD" with the acronym, so it does not sound so bad as when the full phraseology is used with the double dismiss fully pronounced - not just "em tee dee". Either way the meaning does get through.
The results are very preliminary, and even LL says so. And all they would say is CI's improve DC, not the other way around.
I think we might be coming to a final confluence on submission to the MHRA from what Les Goldman told us on Biz. I read between the lines of what he said, in particular they are now double checking which implies the application is all but complete. I would give them one to three months for that. Also on the spoofing lawsuit, Sept 27 is the date for the final submission on the MTD and then it will be in the hands of the Court. Perhaps one month for a ruling that will dismiss the MTD. At that point they will start working to prepare for discovery which I imagine Citadel et Al desperately want to avoid and so will start settlement discussions. so we could see the MAA and a settlement discussions (especially with the added pressure of the MHRA submission) coming one after another perhaps some 3 months out and the share price hopefully will respond to these confluent pressures.
I think he was referring only yo the GBM indication where they will not need much of a sales force as they are already at over 90 of the main locations that treat GBM. He did indicate they are open to partnership for the other solid tumors where they do need to build up a significant sales force. They just need to pay up!
Thanks for that.
Your chosen name LessIsMore says it all. Less for us is more for you.
Well worth hearing with your own eats!
Yes, I now found the icon to navigate the big biz - it is small and at the very bottom of the page - but it is there and it works. But it is only audio, no video. Thank you all.
there is no download icon. Can you send the link?
not on my desk top. Last time I had the same problem until someone was kind enough to send me a different link that did have a rewind and forward button and to the right episode.
But there is no way to navigate to the 20 min mark. I do not want to waste 20 minutes sitting there for Les to start talking.
You are providing a useless link to Big Biz. There is no way to navigate to the episode and time slot for Les. Please provide a usable link.
You are providing a useless link to Big Biz. There is no way to navigate to the episode and time slot for Les. Please provide a usable link.
No one is getting out of this law suit for a mere $3M!
I believe if NWBO get a reasonable settlement (large enough) offer they will take it. They are here to do their thing with GBM and not to score points on how unfair the market really is and do the SEC's job for them.
And you will also see a lot talking about actually having closed automated systems.
I posted:
Thus either of the above will be a disaster for the MMs et al. Even a "mere" settlement will greatly encourage others to get a "mere" settlement as well. Their only shot at salvation is a WIN at trial.
They are going to fight tooth and nail to keep NWBO from getting a judgment against them.
A typical contingency fee could be on the order off 33% or so - but sometimes less if it is a big case. If the law firm believes that the likely pay out will be very large, say something like $1B or more, they may very well settle for less - say 25% or so on a likely $1B - that still leaves the law firm with a pretty hefty fee of a quarter of a BILLION $. This will particularly be true if they believe the case will settle, thus involving much less work for them. Not to mention the huge advertising worth for the firm handling such a huge and visible case.
I should add that while it seems that the standard "wisdom" on the BB is that the case was taken on a contingency basis, I have yet to see ant official acknowledgment that such is the case.
This quote talks of 40 patients in the Direct trial:
Northwest Biotherapeutics Announces Data To Date From DCVax-Direct Phase I Trial
Published: Jun 01, 2015
BETHESDA, Md., June 1, 2015 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, over the weekend in Chicago released promising new data on their Phase I trial of DCVax-Direct for direct injection into all types of inoperable solid tumors.
The patients enrolled in the trial had late stage cancers, with an average of three inoperable tumors. The patients had failed multiple prior therapies and had a poor prognosis.
The trial enrolled 40 patients, and 39 were evaluable. A conservative treatment regimen was used. Although the patients had multiple inoperable tumors, only 1 tumor was injected with DCVax-Direct. The treatments included only 3 injections in the first 2 weeks (Day 0, 7 and 14), and up to 3 additional injections spaced months apart thereafter (Weeks 8, 16 and 32), over a total period of 8 months.
It seems there were AT LEAST 60 tp be given Direct.
DCVax® – Direct
Our DCVax-Direct product offers a potential new treatment option for the wide range of clinical situations in which patients’ tumors are considered “inoperable” because the patient has multiple tumors, or their tumor cannot be completely removed, or the surgery would cause undue damage to the patient and impair their quality of life.
A large number of patients with a variety of cancer types (including lung, colon, pancreatic, liver, ovarian, head and neck, and others) are faced with this situation, because their tumors are already locally advanced or have begun to metastasize by the time symptoms develop and the patients seek treatment. For these patients, the outlook today is bleak and survival remains quite limited.
DCVax-Direct is administered by direct injection into a patient’s tumors. It can be injected into any number of tumors, enabling patients with locally advanced disease or with metastases to be treated. DCVax-Direct can also be injected into tumors in virtually any location in the body: not only tissues at or near the surface of the body but also, with ultra-sound guidance, into interior tissues.
We are currently conducting a 60-patient Phase I/II trial of DCVax-Direct for all types of inoperable solid tumors. The trial is under way at MD Anderson in Houston, TX and MD Anderson in Orlando, FL, with additional sites in varying stages of preparation. The Phase I stage of the trial involves dose escalation, testing 3 different dose levels of DCVax-Direct, and confirmation of the optimal dose. The Phase II stage of the trial will focus on efficacy. The primary measure of efficacy will be regression (i.e., shrinkage or elimination) of the patient’s existing inoperable tumors. Such regression is a rapid endpoint: if it is going to occur, is anticipated to occur within a couple months of treatment.
To learn the eligibility criteria for the DCVax-Direct trial, please visit ClinicalTrials.gov.
I agree. The determination of who are bogus shareholders from naked shorting (if any) will be a prerequisite to any dividend. I certainly do not want to pay any of this $500M to any bogus share holders.
That is certainly a possibility as well. It would probably be a tax issue as to which is better. Leave it to the accountants.
constant conversion and sale
When Cohen Milstein gets a large settlement
this is only a technicality (and not mostly new really). For the most part these increases in the OS shares is largely made up of warrant exercises IMO. For me, this dilution is already in the bag for a long time and already happened (IMO) when the warrants were granted. So the current slow and steady stream of exercises has not really changed much.
From Court Listener - tonight.
114
Jul 12, 2023
MOTION to Dismiss Amended Complaint. Document filed by Canaccord Genuity LLC, Citadel Securities LLC, G1 Execution Services LLC, GTS Securities LLC, Instinet LLC, Lime Trading Corp., Virtu Americas LLC..(Burck, William) (Entered: 07/12/2023)
Main Doc
115
Jul 12, 2023
MEMORANDUM OF LAW in Support re: 114 MOTION to Dismiss Amended Complaint. . Document filed by Canaccord Genuity LLC, Citadel Securities LLC, G1 Execution Services LLC, GTS Securities LLC, Instinet LLC, Lime Trading Corp., Virtu Americas LLC..(Burck, William) (Entered: 07/12/2023)
Main Doc
Does anyone have access to Pacer?
With all this delay, we could all use a little reassuring, particularly from management. Hoping it won't be much longer. (aval hashem tomid ya'azor lanu).
Thanks, I stand corrected.
As today was the due date for the MTD, and I assume that his deadline was met and the MTD filed by 5PM today (or whenever the court closed today). Does anyone have an idea how long it will be before this document will make its way to iHub? I just checked Court Listener and it does not show up there as of yet.
Hoping that your assessment is a good guess at what might happen. iF THIS DOES COME TO PASS IN THE NEAR FUTURE in the NWBO lawsuit, then will this be a good time for the shareholders to file their case against Citadel et al for their damages on the same facts?
You should be sending this to Ex - it was his quote.
Thanks, the number would help. Btw,
to NWBO's MTD
In the case this suit is modeled on the Judge did not allow it.
NWBO has all the cards, and their buyout price. Any BP, even if they want to pay their asking price, cannot justify it to shareholders. That’s valid.
They took down the price many time before & after the release of good pr/ presentation they can do it again on MHRA approval.